Lifestyle makeover for IBD: diet and stress coaching tested alongside meds
NCT ID NCT07168499
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding diet advice and stress management sessions to standard advanced therapy helps people with Crohn's disease or ulcerative colitis reach remission. About 160 adults with active IBD will be split into four groups, each receiving different combinations of dietitian and psychologist visits. The main goal is to see if those getting lifestyle support show greater improvement in symptoms after 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- diet management and stress management
- What this could lead to
- If it works, this could show that combining lifestyle support with medication helps more people with IBD reach remission.
- What could go wrong
- This is a small, early-stage trial with only 160 participants, and the lifestyle interventions are brief. Results may not apply to everyone, and the added benefit over medication alone may be small.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 160 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2025
- Expected to finish
-
May 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Able to provide written informed consent prior to screening and to comply with the requirements of the study protocol. 2. At least 18 years of age 3. Established diagnosis of CD, UC, or IBD-unspecified 4. Recent (within 6 months) objective evidence of active IBD on colonoscopy or intestinal ultrasound or cross-sectional imaging or elevated inflammatory markers (CRP) 5. Initiating advanced therapy (anti-TNF agents, anti-integrin agents, anti-IL12/23, anti-IL23 agents, S1P receptor modulators, JAK inhibitors) for IBD per usual clinical care within 2 weeks of baseline/randomization, regardless of prior exposure to advanced therapies or disease duration 6. Other non-biologic IBD medications must remain stable during the treatment period and no medication changes are planned with the exception of tapering of corticosteroids. 7. Current disease activity defined as a Harvey Bradshaw index \> 4 at baseline (week 0) for CD subjects or Simple Clinical Colitis Activity Index \> 2 at baseline (week 0) for UC subjects or having had a recent exacerbation being treated with systemic steroids or budesonide. Exclusion Criteria: 1. Inability to provide informed consent or unwilling or unlikely to comply with the requirements of the study. 2. Initiation of advanced therapy for extra-intestinal symptoms alone 3. Known eating disorders 4. Already receiving dietary therapy or stress management interventions 5. Severe untreated psychiatric comorbidity including history of suicidal thoughts 6. Evidence of untreated infection (e.g. Clostridium difficile) 7. Presence of stoma or J-pouch 8. Female subjects who are pregnant, lactating, or intending to become pregnant during the study period 9. On total parental nutrition (TPN) or already following a therapeutic diet for IBD.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Crohn disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune aging blood tests predict which older IBD patients thrive on advanced therapies?
- Ulcerative colitis drugs put under the microscope for hidden clot risk
- Triple-Pronged attack on gut inflammation put to the test
- Can a cheap Anti-Inflammatory drug calm ulcerative colitis?
- Can a liquid diet calm Crohn's in kids?
- Which IBD therapy works best for kids? researchers compare two approaches